Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › CA › El Monte › NPI 1518585108
Lab

Fulgent Therapeutics, LLC.

Fulgent Therapeutics, LLC. was paid $1.56M by Medicaid between Jan 2021 and Jun 2022, across 4 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 75% of everything it billed.

33Billing provider infoFULGENT THERAPEUTICS, LLC.
EL MONTE, CA 91731
33aNPI1518585108assigned 07/09/2020
28Total paid$1.56M
24GClaims53,354
24DCodes billed4
24AFirst – last monthJan 2021 – Jun 2022
Compared with peers

Next to other Clinical Medical Laboratory providers in California

Rank by total paid#165 of 561
Median peer was paid$222K
This provider vs. median7.0×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official KIM, PAUL controls 11+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$1.0M$2.0M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
20211,346$28K
202252,008$1.54M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 75% 24,739 21,547 $1.17M
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 14% 16,360 14,174 $214K
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 11% 12,230 10,943 $177K
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B <1% 25 24 $2K

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialKIM, PAUL (CFO)
Parent organizationFULGENT GENETICS, INC
Same official

Other billing entities under KIM, PAUL

Full network →
ProviderLocationPaid
Fulgent Therapeutics, LLC.El Monte, CA$84.90M
Paul H. Kim M.D., INC., a Professional CorporationTorrance, CA$339K
Cal City Urgent CareCalifornia City, CA$227K
Bradshaw Optometry CorpSacramento, CA$176K
Paul J Kim MD INCTustin, CA$157K
DR. P.Kim Podiatry, P.C.Brooklyn, NY$104K
Bradshaw OptometryElk Grove, CA$80K
Grace Hematology and OncologyFletcher, NC$36K
Thinknetic Medical CorporationSan Bernardino, CA$33K
Paul E Kim MD INCSan Diego, CA$11K
Sun City Optometry a Professional CorporationMenifee, CA$685.24

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.